Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.11 Insider Own1.10% Shs Outstand170.42M Perf Week9.42%
Market Cap356.18M Forward P/E39.72 EPS next Y0.05 Insider Trans0.00% Shs Float168.54M Perf Month-8.73%
Income-209.25M PEG- EPS next Q0.05 Inst Own48.28% Short Float11.82% Perf Quarter-1.88%
Sales116.33M P/S3.06 EPS this Y80.92% Inst Trans5.01% Short Ratio3.18 Perf Half Y154.57%
Book/sh-3.85 P/B- EPS next Y113.58% ROA-92.23% Short Interest19.92M Perf Year63.28%
Cash/sh0.48 P/C4.33 EPS next 5Y16.90% ROE- 52W Range0.70 - 3.40 Perf YTD-30.10%
Dividend Est.- P/FCF- EPS past 5Y23.09% ROI-422.11% 52W High-38.53% Beta0.90
Dividend TTM- Quick Ratio0.87 Sales past 5Y7.64% Gross Margin62.67% 52W Low198.57% ATR (14)0.26
Dividend Ex-Date- Current Ratio1.29 EPS Y/Y TTM40.41% Oper. Margin-122.46% RSI (14)42.90 Volatility10.67% 12.64%
Employees240 Debt/Eq- Sales Y/Y TTM54.14% Profit Margin-179.87% Recom1.75 Target Price7.41
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q33.60% Payout- Rel Volume0.79 Prev Close1.91
Sales Surprise12.58% EPS Surprise-3.80% Sales Q/Q71.38% EarningsMay 07 BMO Avg Volume6.26M Price2.09
SMA20-16.34% SMA50-14.56% SMA20017.42% Trades Volume4,928,175 Change9.42%
Date Action Analyst Rating Change Price Target Change
Jan-03-24Downgrade BofA Securities Buy → Neutral
Nov-20-23Resumed JP Morgan Neutral
Aug-01-23Upgrade Northland Capital Under Perform → Market Perform
Jun-15-23Upgrade BofA Securities Underperform → Buy $1.25 → $4
Mar-16-23Downgrade Northland Capital Market Perform → Under Perform $1
Mar-16-23Downgrade BofA Securities Neutral → Underperform $8 → $1.50
Mar-07-23Upgrade Credit Suisse Underperform → Neutral $6.50 → $7
Feb-27-23Resumed BofA Securities Neutral $8
Feb-24-23Upgrade Jefferies Hold → Buy $12
Feb-03-23Upgrade Morgan Stanley Underweight → Equal-Weight $9
Apr-23-24 08:00AM
Apr-21-24 10:39AM
Apr-07-24 02:45PM
Apr-01-24 08:00AM
Mar-28-24 11:30AM
08:00AM Loading…
Mar-26-24 08:00AM
Mar-25-24 04:00PM
Mar-22-24 06:26PM
Mar-04-24 08:28PM
Feb-28-24 08:34AM
Feb-27-24 09:38PM
07:20AM Loading…
Feb-16-24 04:30PM
Feb-15-24 03:13AM
Feb-13-24 10:00AM
Feb-01-24 02:00PM
Jan-23-24 04:00PM
Jan-19-24 08:50AM
Jan-18-24 09:15PM
Jan-03-24 07:00AM
Dec-18-23 08:00AM
04:00PM Loading…
Dec-13-23 04:00PM
Dec-07-23 11:30AM
Nov-13-23 10:30AM
Nov-11-23 11:00AM
Nov-09-23 04:30PM
Nov-08-23 01:16PM
Nov-07-23 08:19AM
Nov-01-23 10:01AM
Oct-31-23 08:00AM
Oct-24-23 08:00AM
Sep-12-23 10:15AM
Aug-31-23 11:31AM
Aug-28-23 08:00AM
Aug-26-23 11:00AM
Aug-11-23 08:00AM
Aug-08-23 04:15PM
Aug-06-23 08:06AM
Aug-02-23 09:06AM
Aug-01-23 07:15AM
Jul-24-23 08:00AM
Jul-18-23 08:00AM
Jul-17-23 06:00AM
Jul-07-23 08:00AM
Jun-28-23 08:00AM
Jun-24-23 02:30PM
Jun-15-23 02:30PM
Jun-08-23 11:30AM
Jun-07-23 09:54AM
Jun-05-23 08:00AM
Jun-01-23 08:00AM
May-25-23 04:30PM
May-24-23 08:00AM
May-12-23 04:30PM
May-10-23 09:55AM
May-09-23 08:25AM
May-04-23 08:30AM
May-01-23 08:00AM
Apr-27-23 08:00AM
Apr-25-23 10:01AM
Apr-19-23 08:42AM
Apr-06-23 05:39PM
Apr-03-23 08:00AM
Mar-23-23 11:30AM
Mar-22-23 04:15PM
Mar-20-23 08:00AM
Mar-18-23 08:52AM
Mar-17-23 12:57PM
Mar-16-23 08:21AM
Mar-10-23 11:05AM
Mar-08-23 08:00AM
Mar-06-23 02:45PM
Mar-04-23 10:30AM
Feb-24-23 01:40PM
Feb-23-23 08:00AM
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Warren EricChief Commercial OfficerSep 20 '23Sale1.2574292468,318Sep 21 05:06 PM
Warren EricChief Commercial OfficerAug 18 '23Sale1.4124334469,060Aug 21 04:32 PM
Warren EricChief Commercial OfficerJul 19 '23Sale1.5810616869,303Jul 20 04:38 PM
Warren EricChief Commercial OfficerJun 21 '23Sale1.4860389469,409Jun 22 04:45 PM
Warren EricChief Commercial OfficerMay 17 '23Sale1.6221935670,012May 18 04:07 PM
CARROLL J MARTINDirectorMay 11 '23Buy1.5723,09136,28536,500May 11 04:11 PM
CARROLL J MARTINDirectorMay 10 '23Buy1.498,40912,54513,409May 11 04:11 PM
ROCAMBOLI STEPHENDirectorMay 10 '23Buy1.508,11112,1268,111May 11 04:10 PM
Koenig Sheldon L.President and CEOMay 09 '23Buy1.2620,00025,192312,816May 10 04:12 PM